Skip to main content
Advanced Technical IVT

therapeutic vulnerability

A molecular weakness in cancer cells that can be exploited by targeted therapies, often resulting from genetic dependencies or pathway addictions.

Full Definition

Therapeutic vulnerability refers to specific molecular dependencies or weaknesses in cancer cells that create opportunities for selective targeting with precision therapies. These vulnerabilities arise from various mechanisms including oncogene addiction, synthetic lethal relationships, loss of tumor suppressor function, or metabolic dependencies. In precision oncology, identifying therapeutic vulnerabilities is central to treatment selection, as targeting these weaknesses can achieve tumor cell death while sparing normal cells. Examples include PARP inhibitor sensitivity in BRCA-deficient tumors and CDK4/6 inhibitor effectiveness in Rb-proficient cancers. Modern precision oncology platforms increasingly focus on vulnerability assessment rather than just mutation detection.

Usage

Usage note: Emphasize exploitability; distinguish from general 'target' terminology.

In Context

  • "BRCA1 loss created a therapeutic vulnerability to PARP inhibition through synthetic lethality." — precision medicine case study
  • "The molecular profiling identified multiple therapeutic vulnerabilities amenable to combination targeting." — molecular tumor board presentation

Also known as

therapeutic target molecular vulnerability

Contrasted with

therapeutic resistance

Don't confuse with

targetable alteration druggable mutation

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON